BridgeBio Pharma, Inc. (BBIO): Cash & Equivalents
$570.12M
As of 2025-12-31
$677.91M
As of 2026-06-30
+14.8%
3-year compound annual growth
+9.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $570.12M | -16.3% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $681.10M | +81.2% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $375.94M | -0.2% | 2026-02-24, Balance as of period end |
| 2022-12-31 | $376.69M | -4.3% | 2025-02-20, Balance as of period end |
| 2021-12-31 | $393.77M | +10.6% | 2024-02-22, Balance as of period end |
| 2020-12-31 | $356.08M | -2.1% | 2023-02-23, Balance as of period end |
| 2019-12-31 | $363.77M | -16.6% | 2022-02-25, Balance as of period end |
| 2018-12-31 | $436.09M | +374.0% | 2021-02-25, Balance as of period end |
| 2017-12-31 | $92.00M | n/a | 2020-03-03, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $570.12M | -16.3% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $93.03M | +58.9% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $296.68M | +33.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $71.33M | -53.7% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $679.57M | +51.1% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $93.68M | -30.9% |
| Insmed Inc (INSM) | 2025-12-31 | $510.44M | -8.0% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $364.41M | -14.6% |
Compare BBIO, TVTX, MIRM, NATR side by side · Screen every company in Pharmaceutical Preparations ↗